STOCK TITAN

Armistice Capital and Steven Boyd Disclose 1.6M-Share Position in RIGL

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Armistice Capital, LLC and Steven Boyd filed a Schedule 13G/A reporting beneficial ownership of 1,600,000 shares of Rigel Pharmaceuticals, representing 8.92% of the outstanding common stock. The filing states these shares are held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital serves as investment manager and over which Armistice Capital and Mr. Boyd share voting and dispositive power.

The filing clarifies the Master Fund retains the economic right to proceeds or dividends while disclaiming direct beneficial ownership due to the investment management agreement. All reported share counts are based on 17,937,340 shares outstanding as of July 31, 2025, per the issuers SEC filing.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Armistice Capital and Steven Boyd disclose an 8.92% stake (1.6M shares) in Rigel, a material passive ownership disclosure under Schedule 13G/A.

This Schedule 13G/A indicates a non-control, investment-manager-managed position where Armistice Capital exercises shared voting and dispositive power over 1,600,000 shares held by the Master Fund. The position equals 8.92% of the class based on 17,937,340 shares outstanding, which exceeds the 5% reporting threshold and is therefore material to holders and market observers. The filing emphasizes passive intent and ordinary-course acquisition consistent with Schedule 13G treatment.

TL;DR: Filing documents shared voting/dispositive authority via an investment manager relationship, with explicit disclaimer of direct Master Fund ownership.

The disclosure clarifies roles: Armistice Capital is the investment manager with voting and investment power; Steven Boyd, as managing member, is identified as a reporting person. The Master Fund retains economic rights to dividends and proceeds but disclaims beneficial ownership due to the management agreement. This delineation is important for governance transparency and for understanding who holds voting influence versus economic interest.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:08/14/2025
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:08/14/2025
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: August 14, 2025 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

Rigel Pharmaceuticals Inc

NASDAQ:RIGL

RIGL Rankings

RIGL Latest News

RIGL Latest SEC Filings

RIGL Stock Data

810.28M
17.68M
2.65%
79.01%
11.18%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO